449 related articles for article (PubMed ID: 24400655)
1. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.
Pratley RE; Fleck P; Wilson C
Diabetes Obes Metab; 2014 Jul; 16(7):613-21. PubMed ID: 24400655
[TBL] [Abstract][Full Text] [Related]
2. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
Del Prato S; Camisasca R; Wilson C; Fleck P
Diabetes Obes Metab; 2014 Dec; 16(12):1239-46. PubMed ID: 25132212
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
Seino Y; Miyata Y; Hiroi S; Hirayama M; Kaku K
Diabetes Obes Metab; 2012 Oct; 14(10):927-36. PubMed ID: 22583697
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
Nauck MA; Ellis GC; Fleck PR; Wilson CA; Mekki Q;
Int J Clin Pract; 2009 Jan; 63(1):46-55. PubMed ID: 19125992
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of fixed-dose combination therapy, alogliptin plus metformin, in Asian patients with type 2 diabetes: A phase 3 trial.
Ji L; Li L; Kuang J; Yang T; Kim DJ; Kadir AA; Huang CN; Lee D
Diabetes Obes Metab; 2017 May; 19(5):754-758. PubMed ID: 28075066
[TBL] [Abstract][Full Text] [Related]
7. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.
Rosenstock J; Wilson C; Fleck P
Diabetes Obes Metab; 2013 Oct; 15(10):906-14. PubMed ID: 23531118
[TBL] [Abstract][Full Text] [Related]
8. Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus.
Del Prato S; Fleck P; Wilson C; Chaudhari P
Diabetes Obes Metab; 2016 Jun; 18(6):623-7. PubMed ID: 26865535
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
Pratley RE; Kipnes MS; Fleck PR; Wilson C; Mekki Q;
Diabetes Obes Metab; 2009 Feb; 11(2):167-76. PubMed ID: 19125778
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
Wu D; Li L; Liu C
Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Pratley RE; Reusch JE; Fleck PR; Wilson CA; Mekki Q;
Curr Med Res Opin; 2009 Oct; 25(10):2361-71. PubMed ID: 19650752
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of alogliptin in patients with type 2 diabetes mellitus: A multicentre randomized double-blind placebo-controlled Phase 3 study in mainland China, Taiwan, and Hong Kong.
Pan C; Han P; Ji Q; Li C; Lu J; Yang J; Li W; Zeng J; Hsieh AT; Chan J
J Diabetes; 2017 Apr; 9(4):386-395. PubMed ID: 27171508
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
Kaku K; Itayasu T; Hiroi S; Hirayama M; Seino Y
Diabetes Obes Metab; 2011 Nov; 13(11):1028-35. PubMed ID: 21682833
[TBL] [Abstract][Full Text] [Related]
14. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Seino Y; Fujita T; Hiroi S; Hirayama M; Kaku K
Curr Med Res Opin; 2011 Nov; 27 Suppl 3():21-9. PubMed ID: 22106975
[TBL] [Abstract][Full Text] [Related]
15. The effect of alogliptin on pulmonary function in obese patients with type 2 diabetes inadequately controlled by metformin monotherapy.
Tai H; Wang MY; Zhao YP; Li LB; Dong QY; Liu XG; Kuang JS
Medicine (Baltimore); 2016 Aug; 95(33):e4541. PubMed ID: 27537577
[TBL] [Abstract][Full Text] [Related]
16. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
Pratley RE; McCall T; Fleck PR; Wilson CA; Mekki Q
J Am Geriatr Soc; 2009 Nov; 57(11):2011-9. PubMed ID: 19793357
[TBL] [Abstract][Full Text] [Related]
17. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus.
Bosi E; Dotta F; Jia Y; Goodman M
Diabetes Obes Metab; 2009 May; 11(5):506-15. PubMed ID: 19320662
[TBL] [Abstract][Full Text] [Related]
18. Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.
Bosi E; Ellis GC; Wilson CA; Fleck PR
Diabetes Obes Metab; 2011 Dec; 13(12):1088-96. PubMed ID: 21733058
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
